GMAB ▲ +11.0% - Genmab A/S
$GMAB Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
05-OCT-2026 02:50 PM ET
Share this post
More filings for $GMAB
GMAB ▼ -3.6% - Genmab A/SNov 5, 2026GMAB ▲ +0.8% - Genmab A/SNov 4, 2026GMAB ▲ +34.1% - Genmab A/SOct 28, 2026GMAB ▲ +25.5% - Genmab A/SOct 28, 2026GMAB ▲ +19.6% - Genmab A/SOct 28, 2026GMAB ▲ +16.1% - Genmab A/SOct 28, 2026
View full $GMAB filing history →💬 Comments
Loading comments…
Leave a comment